
|Articles|October 7, 2008
Hematological Malignancies: Current Perspectives on Diagnosis, Prognosis, and Treatment.
This supplement to ONCOLOGY provides a comprehensive look at state-of-the-art management of three of the most prevalent hematological malignancies in the US today.
Advertisement
This supplement to ONCOLOGY provides a comprehensive look at state-of-the-art management of three of the most prevalent hematological malignancies in the US today: chronic lymphocytic leukemia, non-Hodgkin lymphoma, and acute myeloid leukemia. This supplement is supported by an educational grant from Cephalon Oncology, and is jointly sponsored by Postgraduate Institute for Medicine and Vital Issues in Medicine. CME/PE/CE credit is available.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Related Content
Advertisement

ByJavier Cortés, MD,Aditya Bardia, MD, MPH, FASCO,Kevin Punie,Carlos Barrios,Sara A. Hurvitz, MD,Andreas Schneeweiss, MD,Joohyuk Sohn,Eriko Tokunaga,Adam M. Brufsky, MD, PhD,Yeon Hee Park,Binghe Xu,Roberto Hegg,Mafalda Oliveira,Alessandra Fabi,Natalya Vaksman,Theresa Valdez,Xinrui Zhang,Catherine Lai, MD, MPH,Sara M. Tolaney, MD, MPH




135 Elacestrant in Combination With Everolimus or Abemaciclib in Patients With ER+/HER2– Locally Advanced or Metastatic Breast Cancer (mBC): Phase 2 Results From ELEVATE, an Open-Label, Umbrella Study
ByHope S. Rugo, MD,Sara M. Tolaney, MD, MPH,Nancy Chan,Giuliano Borges,Rinat Yerushalmi,Marina N. Sharifi,Wassim McHayleh,J. Thaddeus Beck,Neelima Vidula, MD,Erika P. Hamilton, MD,Kristine J. Rinn,Joyce O’Shaughnessy, MD,Giuseppe Curigliano,Javier Cortés, MD,Paula Muñoz Romero,Giulia Tonini,Alessandro Paoli,Monica Binaschi,Li Cheng,Jennifer Crozier,Tomer Wasserman,Virginia Kaklamani, MD, DSc
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
How Effective and Safe is EUS-Guided Alpha DaRT in Pancreatic Cancer?
2
FDA Approves Ruxolitinib Tablets for Hematologic Malignancies
3
Unraveling Daraxonrasib’s Breakthrough in Metastatic Pancreatic Cancer
4
Treatment of Patients with FLT3-ITD+ Acute Myeloid Leukemia in Three Phases
5














































